Aprocitentan: New insights

Varzideh, Fahimeh; Kansakar, Urna; Jankauskas, Stanislovas S.; Santulli, Gaetano

doi:10.3389/fcvm.2022.1093406

Cited by 3 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The observations that tTRH is a common clinical condition among hypertensive outpatients without established atherothrombosis and that prevalence of tTRH increases with age and comorbidities [ 55 ] prompted us to explore the possibility that poor concordance with antihypertensive treatment, a well-recognized cause of inadequate BP control [ 56 ], could account for this phenomenon, at least partially. The results of our study support this hypothesis by showing a reduction in BP in 27 patients, who were no longer considered to be tTRH.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic concordance improves blood pressure control in patients with resistant hypertension

Trimarco

Izzo

Mone

et al. 2023

Pharmacological Research

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Therapeutic concordance improves blood pressure control in patients with resistant hypertension

Trimarco

Izzo

Mone

et al. 2023

Pharmacological Research

Self Cite

View full text Add to dashboard Cite

“…A 5 µL aliquot of RNA was then reverse-transcribed using a miScript II RT kit (SABiosciences, Frederick, USA). Triplicate determinations of hsa-miR-130a-5p (MIMAT0004593MIMAT000025) were performed through CFX96 Real-Time System C1000 Touch Thermal Cycler (BioRad Laboratories, Inc., Hercules, California, USA) by using the miScript SYBR Green PCR kit (218073, Qiagen) and specific miScript primer assays (MS00008603, Qiagen) [ 4 , 7 , 18 ]. RT-qPCR data were analyzed using the 2-ΔΔCT method, where cycle threshold values were determined by CFX ManagerTM Software (BioRad Laboratories, Inc., Hercules, California, USA) [ 7 , 18 , 25 ].…”

Section: Methodsmentioning

confidence: 99%

“…In this setting, serum endothelin-1 (ET-1) has been established as one of the main regulators of the endothelium, and a reliable marker of ED in patients with HF [ 3 ]. ET-1 is a vasoconstrictor produced from the prepropeptide big ET-1 by endothelin-converting enzyme, regulating vascular resistance in response to flow change and inflammatory stress [ 4 ]. Indeed, the binding of ET-1 to two G-protein coupled receptors (ETA and ETB) regulates the release of nitric oxide (NO) and/or increases its degradation, which then modulates vasoconstriction, cell proliferation, inflammation, and fibrosis [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Endothelial Dysfunction Drives CRTd Outcome at 1-Year Follow-Up: A Novel Role as Biomarker for miR-130a-5p

Sardu

Santulli²,

Savarese³

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

Endothelial dysfunction (ED) causes worse prognoses in heart failure (HF) patients treated with cardiac resynchronization therapy (CRTd). ED triggers the downregulation of microRNA-130 (miR-130a-5p), which targets endothelin-1 (ET-1). Thus, we evaluated ED and the response to CRTd by assessing miR-130a-5p and ET-1 serum levels. We designed a prospective multi-center study with a 1-year follow-up to evaluate ED, ET-1, and miR-130a-5p in CRTd patients with ED (ED-CRTd) vs. patients without ED (NED-CRTd). Clinical outcomes were CRTd response, HF hospitalization, cardiac death, and all-cause death. At 1-year follow-up, NED-CRTd (n = 541) vs. ED-CRTd (n = 326) patients showed better clinical statuses, lower serum values of B type natriuretic peptide (BNP: 266.25 ± 10.8 vs. 297.43 ± 16.22 pg/mL; p < 0.05) and ET-1 (4.57 ± 0.17 vs. 5.41 ± 0.24 pmol/L; p < 0.05), and higher values of miR-130a-5p (0.51 ± 0.029 vs. 0.41 ± 0.034 A.U; p < 0.05). Compared with NED-CRTd patients, ED-CRTd patients were less likely to be CRTd responders (189 (58%) vs. 380 (70.2%); p < 0.05) and had higher rates of HF hospitalization (115 (35.3%) vs. 154 (28.5%); p < 0.05) and cardiac deaths (30 (9.2%) vs. 21 (3.9%); p < 0.05). Higher miR-130a-5p levels (HR 1.490, CI 95% [1.014–2.188]) significantly predicted CRTd response; the presence of hypertension (HR 0.818, CI 95% [0.669–0.999]), and displaying higher levels of ET-1 (HR 0.859, CI 98% [0.839–0.979]), lymphocytes (HR 0.820, CI 95% [0.758–0.987]), LVEF (HR 0.876, CI 95% [0.760–0.992]), and ED (HR 0.751, CI 95% [0.624–0.905]) predicted CRTd non-response. Higher serum miR-130a-5p levels (HR 0.332, CI 95% [0.347–0.804]) and use of ARNI (HR 0.319, CI 95% [0.310–0.572]) predicted lower risk of HF hospitalization, whereas hypertension (HR 1.818, CI 95% [1.720–2.907]), higher BNP levels (HR 1.210, CI 95% [1.000–1.401]), and presence of ED (HR 1.905, CI 95% [1.238–2.241]) predicted a higher risk of HF hospitalization. Hence, serum miR-130a-5p could identify different stages of ED and independently predict CRTd response, therefore representing a novel prognostic HF biomarker.

show abstract

Aprocitentan: a new emerging prospect in the pharmacotherapy of hypertension

Naseralallah,

Koraysh

2024

Blood Pressure

View full text Add to dashboard Cite

Aprocitentan: New insights

Cited by 3 publications

References 12 publications

Therapeutic concordance improves blood pressure control in patients with resistant hypertension

Therapeutic concordance improves blood pressure control in patients with resistant hypertension

Endothelial Dysfunction Drives CRTd Outcome at 1-Year Follow-Up: A Novel Role as Biomarker for miR-130a-5p

Aprocitentan: a new emerging prospect in the pharmacotherapy of hypertension

Contact Info

Product

Resources

About